logo-loader
AIM:SKIN

Integumen

Receive alerts
Market:
AIM
Market Cap:
£28.05 m
Price
2.60 GBX
Change
4.42%
52 weeks high
2.70
52 weeks low
0.70

In brief

Human Surface Science

Artificial intelligence, clinical research, medical device and life science.

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

Deep dive We explore the investor case for growth companies

Snapshot

  • Lead product is Labskin, a laboratory-grown skin which allows to skip animal testing 
  • A database and an AI version are being developed as well
  • Has begun production of monitoring bacteria reagent

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Coronavirus test makers could be about to cash in as US heads for winter crunch

Laboratory operators in the US have said a lack of capacity has created a backlog of tests that are being processed too slowly to stem the tide of infections

2 weeks, 5 days ago